首页> 外国专利> AN GENE ENGINEERING RECOMBINANT ANTI-CEA, ANTI-CD3 AND ANTI-CD28 SINGLE-CHAIN TRI-SPECIFIC ANTIBODY

AN GENE ENGINEERING RECOMBINANT ANTI-CEA, ANTI-CD3 AND ANTI-CD28 SINGLE-CHAIN TRI-SPECIFIC ANTIBODY

机译:基因工程重组抗CEA,抗CD3和抗CD28单链三特异性抗体

摘要

This invention refers to a linear single chain recombinant trispecific antibody (scTsAb). This trispecific antibody is composed of an anti-carcinoembryonic antigen (CEA), an anti-CD3, and an anti-CD28 (CEA-scTsAb). More specifically, a Fc linking peptide fuses the anti-CEA single chain fragment (scFv) to the anti-CD3 scFv, and an HSA linking peptide fuses the anti CD3 scFv to the anti-CD28 heavy variable chain (V H ) in tandem. A c-myc-tag and/or (His) 6-tag is attached to the C terminal of the CEA-scTsAb either alternatively or simultaneously. This invention also refers DNA sequence coding for the said scTsAbs, plasmids containing the said sequences, and host cells containing the said plasmids. These invented scTsAbs are intended for use in the development of therapeutic drug candidate for treatment of human colon cancer.
机译:本发明涉及线性单链重组三特异性抗体(scTsAb)。该三特异性抗体由抗癌胚抗原(CEA),抗CD3和抗CD28(CEA-scTsAb)组成。更具体地说,Fc连接肽将抗CEA单链片段(scFv)与抗CD3 scFv融合,而HSA连接肽将抗CD3 scFv与抗CD28重可变链(V H)串联融合。 c-myc标签和/或(His)6标签可替代地或同时地附接到CEA-scTsAb的C末端。本发明还涉及编码所述scTsAb的DNA序列,含有所述序列的质粒和含有所述质粒的宿主细胞。这些发明的scTsAb旨在用于开发用于治疗人结肠癌的治疗药物候选物。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号